您当前的位置:
Fluconazole. (Synonyms: 氟康唑; UK-49858)
目录号: PC12932 纯度: ≥98%

三唑抗真菌剂,Fluconazole是抗真菌化合物,可用于表面和全身性的真菌感染。

CAS No. :86386-73-4
商品编号 规格 价格 会员价 是否有货 数量
PC12932-100mg 100mg ¥392.00 请登录
PC12932-1g 1g ¥490.00 请登录
PC12932-5g 5g ¥1470.00 请登录
PC12932-10mM (in 1mL DMSO) 10mM (in 1mL DMSO) ¥539.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Fluconazole.
中文别名
氟康唑;2-(2,4-二氟苯基)-1,3-双(1H-1,2,4-三唑-1-基)-2-丙醇;大扶康;麦道氟康;Α-(2,4-二氟苯基)-Α-(1H-1,2,4-三唑-1-基甲基)-1H-1,2,4-三唑-1-基乙醇;2-(2,4-二氟苯基)-1,3-双(1H-1,2,4-三氮唑-1-基)-2-丙醇;Fluconazole 氟康唑;zzstandard 品牌 氟康唑对照品;博柔霉素;氟康唑 EP标准品;氟康唑 Fluconazole;氟康唑 USP31;氟康唑 USP标准品;氟康唑 标准品;氟康唑的用途以及物理性状;氟康唑峰鉴别 EP标准品;氟康唑工厂;氟康唑杂质;氟康唑杂质对照品;氟康唑中间体;格列本脲;抗真菌药 氟康唑;赛庚啶;盐酸环苯扎林;Α-(2,4-二氟苯基)-Α-(1H-1,2,4-三唑-1-基甲基)-1H-1,2,4-三;氟康唑,大扶康,麦道氟康;福司氟康唑杂质A;福司氟康唑杂质1;氟康唑,医药级,纯度:>99%;高纯度,氟康唑原粉,可小包装零售
英文名称
Fluconazole
英文别名
Fluconazole;a.-(2,4-Difluorophenyl)-a-(1H-1,2,4,-triazol-1-ylmethyl)-1H-1,2 ,4-triazole-1-ethanol;2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol;Fluconazole solution;FLUCONAZOLE(RG);UK-49858;2,4-Difluoro-alpha,alpha-1-bis(1H-1,2,4-triazol-1-ylmethyl)benzylalcohol;diflucan;Difluean;Elazor;Fluconal;FluMycon;Flunazol;Flusol;triflucan;UK 49858;Zoltec;Fosfluconazole Impurity 1;2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol;alpha-(2,4-Difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol;2,4-Difluoro-alpha,alpha1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol;[ "" ];Biozolene;Biocanol;Fluconazol;Fungata;Fluconazolum;Pritenzol;Flucazol;Flunizol;Flukezol;Flucostat;Zonal;Alflucoz;Oxifugol;Forcan;Cryptal;Syscan;Canzol;Dimycon;Zemyc;Baten;Mutum;Fluconazolum [Latin];Fluconazol [Spanish];2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1
Cas No.
86386-73-4
分子式
C13H12F2N6O
分子量
306.27
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
产品详情
三唑抗真菌剂,Fluconazole是抗真菌化合物,可用于表面和全身性的真菌感染。
生物活性

Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against Candida albicans. Fluconazole inhibits C. albicans and Candida kefyr with IC99s range from 0.20 μg/mL to 0.39 μg/mL.

性状

Solid

体外研究(In Vitro)

Fluconazole inhibits 4 species ofAspergillus fumigatus with the IC50s of 23.9-43.5 μg/mL. Fluconazole (0.20 μg/mL) inhibits significantly the mycelial-phase growth and germ tube elongation of C. albicans in a medium supplemented with serum.
Fluconazole is a triazole antifungal agent that has been available for the treatment of infections due to Candida, Cryptococcus. The MIC90 is highest for C. krusei (MIC ≥ 64 μg/mL) and C. glabrata (MIC, 32 μg/mL) and is ≤2 μg/mL for C. albicans (0.5 μg/mL), C. parapsilosis (2 μg/mL), C. tropicalis (2 μg/mL), C. lusitaniae (2 μg/mL), and C. kefyr (0.5 μg/mL).
Fluconazole (0.1-50.0 μg/mL) damages the fungal cells and reduces their viability.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: C.albicans yeast cells (strain ATCC 26310 and strain TW)
Concentration: 0.1, 0.5, 5.0, 50.0 μg/mL
Incubation Time: 24 hours
Result: The MICs against both strains were 0.5 μg/mL.
体内研究(In Vivo)

Fluconazole ( 0, 0.5, 1, 2.5, 5, 7.5, and 10 mg/kg; administered intraperitoneally (i.p.) as a single dose) results in a 50% reduction in fungal densities (ED50) of 4.87 mg/kg in a murine model of systemic candidiasis. Fluconazole exhibits terminal elimination half-life of 2.4 h) following i.p. administration.The terminal half-life does not change with the dose of fluconazole administered.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female NYLAR mice (weight, 18 to 20 g; infected intravenously with C. albicans blastoconidia)
Dosage: 5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis)
Administration: Given i.p. as a single dose
Result: T1/2=2.4 h
运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
ClinicalTrial
参考文献
溶解度数据
体外研究: 

DMSO : ≥ 100 mg/mL (326.51 mM)

H2O : 2 mg/mL (6.53 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.2651 mL 16.3255 mL 32.6509 mL
5 mM 0.6530 mL 3.2651 mL 6.5302 mL
10 mM 0.3265 mL 1.6325 mL 3.2651 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.16 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.16 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.16 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 4.

    建议依照次序添加每种溶剂: PBS

    Solubility: 2 mg/mL (6.53 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2